Effect of the Local Application of Ciclosporine A on Chronic Erosive Lichen planus of the Oral Cavity

Françès, Camille; Boisnic, S; Etienne, Sylvie; Szpirglas, H

doi:10.1159/000248548

Cited by 61 publications

(22 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were collected 1-4 h after the swish-and-spit medi cation. Frances et al [8] used much lower CS dosages (100 mg a day) in 4 patients but still had good results. In all the treated patients CS concentration was measurable in blood samples.…”

Section: Discussionmentioning

confidence: 99%

Lack of Effect after Local Treatment with a New Ciclosporin Formulation in Recalcitrant Erosive Oral Lichen planus

Itin

Surber²,

Büchner³

1992

Dermatology

View full text Add to dashboard Cite

We treated 7 patients with recalcitrant enoral lichen planus (Lp) with a new hydrophilic ciclosporin (CS) formulation during 8 weeks. The preparation with proven in vivo percutaneous absorption was designed for topical use and contained 100 mg CS/g formulation. The patients applied a cumulative daily dose of about 126 mg CS. We did not see the previously reported clinically impressive response with our CS formulation. No CS was detected in the blood of our patients. We conclude that percutaneous absorption of CS is not the key event to the clinical responses. Clinical benefit after CS in enoral Lp seems rather to be related to a systemic effect of the drug.

show abstract

Section: Discussionmentioning

confidence: 99%

Lack of Effect after Local Treatment with a New Ciclosporin Formulation in Recalcitrant Erosive Oral Lichen planus

Itin

Surber²,

Büchner³

1992

Dermatology

View full text Add to dashboard Cite

show abstract

“…Cyclosporin Cyclosporin has been used as a topical mouthwash with some benefit in four patients with OLP (Frances et al, 1988), and this has been confirmed (Balato et al, 1989). Subsequently, Eisen et al (1990a,b) used cyclosporin again as a mouthwash, but in significantly higher doses of 500 mg three times daily for eight weeks, and showed improvement in patients with atrophic and erosive OLP.…”

Section: Corticosteroidsmentioning

confidence: 94%

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

476

461

View full text Add to dashboard Cite

Lichen planus (LP) is a relatively common disorder of the stratified squamous epithelia, which is, in many ways, an enigma. This paper is the consensus outcome of a workshop held in Switzerland in 1995, involving a selection of clinicians and scientists with an interest in the condition and its management. The oral (OLP) eruptions usually have a distinct clinical morphology and characteristic distribution, but OLP may also present a confusing array of patterns and forms, and other disorders may clinically simulate OLP. Lesions may affect other mucosae and/or skin. Lichen planus is probably of multifactorial origin, sometimes induced by drugs or dental materials, often idiopathic, and with an immunopathogenesis involving T-cells in particular. The etiopathogenesis appears to be complex, with interactions between and among genetic, environmental, and lifestyle factors, but much has now been clarified about the mechanisms involved, and interesting new associations, such as with liver disease, have emerged. The management of lichen planus is still not totally satisfactory, and there is as yet no definitive treatment, but there have been advances in the control of the condition. There is no curative treatment available; immunomodulation, however, can control the condition. Based on the observed increased risk of malignant development, OLP patients should be offered regular follow-up examination from two to four times annually and asked to report any changes in their lesions and/or symptoms. Follow-up may be particularly important in patients with atrophic/ulcerative/erosive affections of the tongue, the gingiva, or the buccal mucosa. Much more research is required into the genetic and environmental aspects of lichen planus, into the premalignant potential, and into the possible associations with chronic liver, and other, disorders. More clinical studies are required into the possible efficacy of immunomodulatory drugs such as pentoxifylline and thalidomide.

show abstract

“…Topical cyclosporine has been reported to be effective in the management of a variety of oral mucosal disorders (Table II), [58][59][60][61][62][63][64][65] although it appears to be less effective and more expensive than topical tacrolimus or pimecrolimus for the management of such diseases. 33 Oral lichen planus.…”

Section: Topical Cyclosporinementioning

confidence: 99%